Stacking considerations: DSIP combines reasonably well with certain other peptides and supplements, though caution is warranted
A small number of patients report mild reactions including nausea, slight discomfort at the injection site, or temporary tiredness
The situation is constantly evolving as more data on the health benefits of weight loss becomes available
Phase 2 dose-escalation data showed mean weight loss of 24.2% at 48 weeks at the highest dose tested substantially exceeding semaglutide's 14.9% and approaching tirzepatide's 22.5% in comparable timeframes
Read Retatrutide vs Semaglutide

Pre-treatment: Measure morning resting heart rate for 7 days Consider baseline ECG if not done recently Review all medications for cardiac interactions Discuss with physician specifically about the glucagon receptor heart rate effect During treatment: Measure resting heart rate daily during dose escalation Continue at each dose for minimum 6 to 8 weeks before increasing If resting HR exceeds baseline by more than 10 BPM, hold dose If resting HR exceeds 90 BPM at rest consistently, consult physician before any further increases Consider microdosing approach for ultra-gradual escalation Expected timeline: Weeks 1-12: very gradual heart rate change at low doses Weeks 12-30: moderate increase as dose slowly climbs Weeks 30+: stabilization (may occur later than standard protocol due to slower escalation) Protocol 3: monitoring-enhanced approach for data-driven researchers Who this is for: Researchers who want comprehensive data, athletes tracking performance metrics, anyone who finds data reassuring
